RxSight Realigns Top Management

There’s a new tenant in RxSight Inc.’s corner office. The company has appointed Aziz Mottiwala as president and CEO, succeeding Ron Kurtz, M.D., who will continue to serve as chief medical officer.

“We are excited to welcome Aziz to RxSight and believe his deep commercial and operational experience in eye care makes him exceptionally well suited to lead the company into its next chapter of value creation,” RxSight Board Chairman Andy Corley stated. “On behalf of the board, I want to express our sincere appreciation to Ron for his vision and leadership in establishing adjustability in the ophthalmic marketplace, and for his continued commitment to advancing our technology and clinical value as chief medical officer. Ron’s track record of product development is well known throughout the ophthalmic community, and we look forward to his continued leadership as we expand adjustability into broader market segments.”

Mottiwala has extensive commercial leadership experience across eye care, with a proven track record of building and scaling high-performing commercial organizations. He most recently served as chief commercial officer at Tarsus Pharmaceuticals and previously held the same role at Opiant Pharmaceuticals. Before that, he spent more than a decade at Allergan, where he held senior leadership positions across the company’s eye care franchise and broader commercial organization. Mottiwala earned a bachelor of science degree in biochemistry from the University of California, San Diego, and an MBA from the University of Southern California.

“I am excited and honored to join RxSight at such a critical time for the company,” Mottiwala said. “RxSight has created a unique and differentiated platform with significant opportunity ahead. Adjustability has brought a new level of accuracy and customization to modern cataract surgery that is still in the early stages of market adoption.”

In connection with this transition, Dr. Kurtz resigned from the Board of Directors; Mottiwala assumed his spot on the governing body.

“RxSight is well positioned to further its mission of transforming cataract surgery through adjustability, making this the right time for me to focus on areas where I can have the greatest impact,” Dr. Kurtz commented. “I look forward to working closely with Aziz, the RxSight team, and our clinical partners to continue bringing life-changing innovations and personalized vision to patients.”

RxSight Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight Light Adjustable Lens system, comprising the RxSight Light Adjustable Lens (LAL/LAL+, collectively the LAL), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery, according to the company.